ArticleCell cycle (Georgetown, Tex.)2016
Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors.
Article in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.Frontiers in immunology · 2026Article
- Apoptosis-induced translocation of nesprin-2 from the nuclear envelope to mitochondria is associated with mitochondrial dysfunction.Nucleus (Austin, Tex.) · 2024Article
- EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas.Frontiers in oncology · 2024Article
- LncRNA MAFG-AS1 is involved in human cancer progression.European journal of medical research · 2023Review
- Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.FEBS open bio · 2023Article
- A cis-acting mechanism mediates transcriptional memory at Polycomb target genes in mammals.Nature genetics · 2021Article
- Transcriptomics-Based Repositioning of Natural Compound, Eudesmin, as a PRC2 Modulator.Molecules (Basel, Switzerland) · 2021Article
- Functional relationship of SNP (Ala490Thr) of an epigenetic geneJournal of genetics · 2021Article
- PRC2 is high maintenance.Genes & development · 2019Review
- An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.Nature communications · 2019Article
- Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.Leukemia · 2018Article
- Association of clinicopathologic characteristics and outcomes withOncoTargets and therapy · 2018Article
- Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EZH2, the main catalytic component of the Polycomb Repressive Complex 2 (PRC2) is apparently upregulated in most solid tumors. Furthermore its expression generally associates with poor prognosis. It was proposed that this correlation reflects a causal event, EZH2 mediating the silencing of key tumor suppressor loci. In contrast, we recently showed that EZH2 is dispensable for solid tumor development and that its elevated expression reflects the abnormally high proliferation rate of cancer cells. Here, we investigate the functional association between EZH2 expression and silencing of key tumor suppressor loci and further illustrate the confounding effect of proliferation on EZH2's association to outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.